|1.||Lindegren, S: 3 articles (01/2001 - 01/2000)|
|2.||Horvath, G: 3 articles (01/2001 - 01/2000)|
|3.||Jacobsson, L: 3 articles (01/2001 - 01/2000)|
|4.||Andersson, H: 3 articles (01/2001 - 01/2000)|
|5.||Leser, G: 3 articles (01/2001 - 01/2000)|
|6.||Luison, Elena: 2 articles (10/2009 - 12/2005)|
|7.||Coliva, Angela: 2 articles (10/2009 - 12/2005)|
|8.||Giussani, Augusto: 2 articles (10/2009 - 12/2005)|
|9.||Canevari, Silvana: 2 articles (10/2009 - 12/2005)|
|10.||Figini, Mariangela: 2 articles (10/2009 - 12/2005)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
01/01/2000 - "The purpose of the present study was to investigate the therapeutic efficacy of 211At-labelled specific monoclonal antibody MOv18 in nude mice with intraperitoneal growth of the human ovarian cancer cell line OVCAR3. "
01/01/2001 - "Comparison of the therapeutic efficacy of 211At- and 131I-labelled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer."
01/01/2000 - "Female nude mice were inoculated intraperitoneally with 1 x 10(7) cells of the human ovarian cancer cell line NIH:OVCAR 3. After about two weeks they were injected with the 211At-labelled specific monoclonal antibody MOv18 intraperitoneally. "
01/01/2000 - "The curative and palliative potential of the monoclonal antibody MOv18 labelled with 211At in nude mice with intraperitoneally growing ovarian cancer xenografts--a long-term study."
09/01/2002 - "Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study."
01/01/1991 - "Preclinical pharmacokinetics and localization studies of the radioiodinated anti-ovarian carcinoma MAb MOv18."
01/01/1995 - "The human anti-(mouse Ig) antibody (HAMA) response was measured in serum of 52 patients suspected of having ovarian carcinoma who had received an i.v. injection of either the murine monoclonal antibody (mAb) OV-TL 3 F(ab')2 (n = 28, 1 mg) or the chimeric mouse/human mAb MOv18 (cMOv18; n = 24, 3 mg). "
11/01/1992 - "Monoclonal antibody (Mab) MOv18 preferentially reacts with gynecological carcinomas. "
07/01/1990 - "Over a period of approximately 1 year, the immunoreactivity of the anti-ovary carcinoma MAb MOv18 was evaluated after radiolabelling with 125I on two different ovarian carcinoma cell lines, OvCa432 and IGROV1. "
04/15/1988 - "In the perspective of in vivo therapeutic applications, the monoclonal antibody (MAb) MOv18 was selected for its restricted reactivity with human ovarian carcinoma. "
07/01/2000 - "We investigated the safety and pharmacokinetics of (131)I-labeled chimeric monoclonal antibody MOv18 ((131)I-c-MOv18 IgG) in patients with ovarian cancer and the estimated radiation dose to cancer-free organs and tumor. "
01/01/1991 - "The in vivo behavior of the monoclonal antibody (MAb) MOv18, with a restricted specificity for human ovarian carcinoma was analyzed on normal and tumor-bearing animals. "
10/31/1989 - "The reactivity profile of the monoclonal antibody (MAb) MOv18, raised against a poorly differentiated ovarian carcinoma specimen, was studied on normal tissues and tumors from the female reproductive system and on the kidney, which like the oviducts, vagina and uterus, also derives from the intermediate mesoderm. "
01/01/1991 - "We have selected a monoclonal antibody (MOv18) reactive with ovarian carcinoma, which exhibits a restricted tumor specificity, a high affinity constant and which recognizes a 38-kDa glycoprotein homogeneously expressed on the cell surface of 90% of human ovarian carcinomas. "
|1.||Folic Acid (Vitamin M)
|2.||Carrier Proteins (Binding Protein)
|3.||Immunoglobulin G (IgG)
|6.||Complementary DNA (cDNA)
|7.||T-Cell Antigen Receptors (T-Cell Receptor)
|8.||Membrane Glycoproteins (Membrane Glycoprotein)
|1.||Heterologous Transplantation (Xenotransplantation)